You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):達伯舒兩項新增適應症、耐立克新藥及達攸同、達伯華、蘇立信多項新增適應症納入2022年版國家醫保藥品目錄
格隆匯 01-18 21:37

格隆匯1月18日丨信達生物(01801.HK)公吿,公司新增五款產品(含新增適應症)成功納入新版《國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年)》,其中包括:PD-1抑制劑達伯舒(信迪利單抗注射液)在原基礎上新增兩項適應症納入國家醫保藥品目錄(談判藥品目錄);耐立克(奧雷巴替尼)首次納入國家醫保目錄(談判藥品目錄);達攸同(貝伐珠單抗注射液)、達伯華(利妥昔單抗注射液)及蘇立信(阿達木單抗注射液)三個藥品新增多項適應症納入國家醫保藥品目錄(常規目錄)。新版國家醫保藥品目錄將於2023年3月1日起正式實施。

近年來,中國持續深化醫療保障制度改革,保障人民健康,取得了有目共睹的積極成果。在這個過程中,公司始終堅持開發出老百姓用得起的高品質生物的企業使命,積極迴應國家政策,為健康中國戰略貢獻力量。公司將繼續積極配合政府的醫保政策在各統籌地區落地,讓高品質藥物儘快惠及更多中國患者及其家庭。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account